PlainPharmaWatch

CMS Open Payments · Program Year 2024

Alcresta Therapeutics, Inc.

Alcresta Therapeutics, Inc. reported $170,171.73 across General Payments, Research, and Ownership to 869 physicians and teaching hospitals across 869 transactions.

See the rankings → How this is sourced
$170.2K
All-tracks total
869
Transactions
869
Recipients
−$116.0K
General Payments vs PY2023

Alcresta Therapeutics, Inc. reported $170,171.73 across all CMS Open Payments tracks (General + Research + Ownership) to 869 physicians and teaching hospitals in Program Year 2024 - ranking #1048 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $170,171.73, averaging $195.82 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer alcresta-therapeutics-inc Alcresta Therapeutics, Inc.

$170.2K · #1048/1,925 · 0.0% industry · PY2024

  • TOT $170.2K
  • RANK #1048
  • SHARE 0.0%
  • TXN 869
  • RCP 869
  • CAT 3
  • GEN $170.2K
  • ΔGEN −$116.0K
  • TOP1 24.5%
  • PY 2024

Volume peers

Nearest volume peer: Clozex Medical Inc ($170.2K)

Clozex Medical Inc$170.2KAlcresta Therapeutics, Inc. …$170.2KDraeger Medical Systems, Inc$169.2KQuanta Dialysis Technologies…$169.2KHexal AG$168.9K
All-tracks payment totals near Alcresta Therapeutics, Inc. (CMS Open Payments PY2024)

Alcresta Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Alcresta Therapeutics, Inc.'s CMS-reported General Payments decreased by $116.0K (−40.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: ALCRESTA THERAPEUTICS, INC.PY2023: ALCRESTA THERAPEUTICS, INC.PY2024: Alcresta Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$286.2KPY2024$170.2K
PY2023
$286,203.06
PY2024
$170,171.73

What the Data Shows for Alcresta Therapeutics, Inc.

Averaging $195.82 per transaction and $195.82 per recipient, Alcresta Therapeutics, Inc.'s Program Year 2024 total comes to $170,171.73 across 869 transactions and 869 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1048 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 3 general-payment categories charted below, "Honoraria" is the largest at $126.2K across 50 transactions, 74.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Honoraria" leads Alcresta Therapeutics, Inc.'s 3-category general-payment breakdown at $126.2K, 74.2% of the reported total.

How Alcresta Therapeutics, Inc. divides its payments

Ranked by total dollars reported per category

1. Honoraria$126.2K2. Food and Beverage$33.9K3. Travel and Lodging$10.1K
Payment Type Amount Transactions
Honoraria $126.2K 50
Food and Beverage $33.9K 766
Travel and Lodging $10.1K 53

Recipient Concentration in General Payments

The five largest recipient relationships account for $113,352.07 (66.6%) of $170,171.73 in this company's General Payments records across 556 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Alcresta Therapeutics, Inc.

The five named recipients with the highest reported General Payments from this company

Valeria Cohran$41.7KCandi Jump$23.9KStephanie Abrams$23.2KAkash Pandey$15.0KMary Garcia$9.5K
  1. 1

    Valeria Cohran

    $41,743.08 across 48 reported transactions

  2. 2

    Candi Jump

    $23,944.58 across 25 reported transactions

  3. 3

    Stephanie Abrams

    $23,158.38 across 20 reported transactions

  4. 4

    Akash Pandey

    $15,034.27 across 13 reported transactions

  5. 5

    Mary Garcia

    $9,471.76 across 8 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Alcresta Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Alcresta Therapeutics, Inc..

Pathway Medical Partners, LLC

HHI 1140

Visionix USA, Inc

HHI 1138

Asensus Surgical, Inc.

HHI 1147

Anika Therapeutics, Inc.

HHI 1135

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Alcresta Therapeutics, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Alcresta Therapeutics, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.